These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 9704724

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
    Négrier S, Caty A, Lesimple T, Douillard JY, Escudier B, Rossi JF, Viens P, Gomez F.
    J Clin Oncol; 2000 Dec 15; 18(24):4009-15. PubMed ID: 11118461
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Soori G, Dillman RO, Wiemann MC, Stark JJ, Tai F, DePriest CB, Church CK, Schulof R.
    Cancer Biother Radiopharm; 2002 Apr 15; 17(2):165-73. PubMed ID: 12030110
    [Abstract] [Full Text] [Related]

  • 6. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
    Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T.
    N Engl J Med; 1998 Apr 30; 338(18):1272-8. PubMed ID: 9562581
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M.
    Clin Cancer Res; 2000 Sep 30; 6(9):3442-50. PubMed ID: 10999727
    [Abstract] [Full Text] [Related]

  • 8. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J.
    J Clin Oncol; 1992 Mar 30; 10(3):414-21. PubMed ID: 1482425
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, De Mulder PH.
    Br J Cancer; 2000 Feb 30; 82(4):772-6. PubMed ID: 10732744
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.
    Vogelzang NJ, Lipton A, Figlin RA.
    J Clin Oncol; 1993 Sep 30; 11(9):1809-16. PubMed ID: 8355047
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.
    Escudier B, Chevreau C, Lasset C, Douillard JY, Ravaud A, Fabbro M, Caty A, Rossi JF, Viens P, Bergerat JP, Savary J, Négrier S.
    J Clin Oncol; 1999 Jul 30; 17(7):2039-43. PubMed ID: 10561255
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
    Clark JI, Mehrabi J, Sosman JA, Logan TF, Margolin KA, Dutcher JP, Urba WJ, Ernstoff MS, McDermott DF, Lau AM, Atkins MB.
    J Immunother; 2007 Jul 30; 30(8):839-46. PubMed ID: 18049336
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09.
    Dillman RO, Wiemann MC, Tai DF, Depriest CB, Soori G, Stark JJ, Mahdavi K, Church CK.
    Cancer Biother Radiopharm; 2006 Apr 30; 21(2):130-7. PubMed ID: 16706633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.